Achilles Therapeutics plc (NASDAQ:ACHL) Short Interest Up 1,280.4% in February

Achilles Therapeutics plc (NASDAQ:ACHL) was the target of a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 797,900 shares, a growth of 1,280.4% from the January 31st total of 57,800 shares. Based on an average trading volume of 764,400 shares, the short-interest ratio is currently 1.0 days. Approximately 2.1% of the shares of the stock are short sold.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. XTX Topco Ltd bought a new stake in shares of Achilles Therapeutics in the 4th quarter valued at approximately $31,000. Two Sigma Advisers LP lifted its position in Achilles Therapeutics by 52.7% in the fourth quarter. Two Sigma Advisers LP now owns 34,200 shares of the company’s stock worth $39,000 after buying an additional 11,800 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in Achilles Therapeutics during the fourth quarter worth $57,000. Two Sigma Investments LP increased its position in Achilles Therapeutics by 190.1% during the fourth quarter. Two Sigma Investments LP now owns 61,637 shares of the company’s stock valued at $70,000 after acquiring an additional 40,388 shares during the last quarter. Finally, BML Capital Management LLC raised its stake in shares of Achilles Therapeutics by 555.8% in the third quarter. BML Capital Management LLC now owns 4,100,002 shares of the company’s stock valued at $4,182,000 after acquiring an additional 3,474,828 shares during the period. 56.38% of the stock is owned by hedge funds and other institutional investors.

Achilles Therapeutics Trading Up 0.4 %

Shares of ACHL traded up $0.01 during mid-day trading on Thursday, reaching $1.39. The company’s stock had a trading volume of 94,889 shares, compared to its average volume of 1,153,383. The company’s fifty day moving average price is $1.22 and its two-hundred day moving average price is $1.03. Achilles Therapeutics has a 52 week low of $0.63 and a 52 week high of $1.76. The stock has a market cap of $56.92 million, a PE ratio of -0.84 and a beta of 1.32.

Achilles Therapeutics Company Profile

Achilles Therapeutics plc, a biopharmaceutical company, develops precision T cell therapies to treat solid tumors. Its platform identifies mutations formed early in the development of cancer. The company offers PELEUS, a proprietary AI-powered bioinformatics platform, used to identify clonal neoantigens in a patient.